Drugs.com - Clinical Trials

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

SYDNEY, June 11, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas...

Jun 26, 2025 - 03:05
 0
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
SYDNEY, June 11, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas...
Read More

Tags:

Previous Article

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation fo...

Next Article

Halocell Energy launches ‘Australian-made’ perovskite PV module for low-light co...

Related Posts

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Final Data From the Phase 3 MYR301 Study Demonstrated L...

May 14, 2025  0

Higher Dose of Wegovy Provided Average Weight Loss of 21% in People with Obesity With a Third Achieving 25% or More

Higher Dose of Wegovy Provided Average Weight Loss of 2...

Jun 21, 2025  0

Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia

Cellenkos Announces US FDA Orphan Drug Designation Gran...

May 12, 2025  0